Incyte Corporation

Incyte Holdings Corporation

Steven M Friedman

Krishna Vaddi

Peggy Ann Scherle

Jordan S Fridman

Xiangdong Liu

Timothy C Burn

Gregory Franklin Hollis

Robert Newton

Reid Huber

Phillip C C Liu

The present invention relates to compositions, methods and kits based on the ADAM-mediated cleavage of Her-2. The present invention also relates to treatments for cancer, and in particular, breast cancer, by modulating the ADAM-mediated cleavage of Her-2. Further, the invention relates to compositions, methods and kits based on the surprising synergistic effect between inhibition of Her-2 cleavage by an ADAM and certain cytostatic (e.g., Herceptin) and cytotoxic (e.g., Taxol) compounds in, among other things, inhibiting tumor cell proliferation and inducing cell death. Additionally, the invention relates to novel variants of ADAM15, designated ADAM15 variant 1 and ADAM15 variant 2, now identified and isolated.

Compositions, methods and kits relating to HER-2 cleavage

Compositions, methods and kits relating to Her-2 cleavage

The present invention is directed to pharmaceutical methods for the treatment of CD30 positive diseases, such as Hodgkin's disease, by administration of a combination of at least one sheddase inhibitor and at least one anti-CD30 immunotherapeutic.

Sheddase inhibitors combined with CD30-binding immunotherapeutics for the treatment of CD30 positive diseases

Growing community of inventors

West Chester, PA, United States of America

Steven M Friedman